Hormones
Does it affect thyroid function?
Thyroid hormone levels, usually reported as a safety measure rather than a goal.
9,491
people in trials
5
human studies
0
compounds, animal or cell only
3
trials found nothing
Measured in people
Ranked by how many people, which is a fact about the evidence and not a judgement about the compound. The one at the top is the most studied, which is not the same as the best. Counts are never added across compounds, because the same person can appear in more than one trial.
- 9,463 people1 human study
9,463 adults aged 40 and over with type 2 diabetes and cardiovascular disease, 610 sites, 28 countries, randomised 1:1 to albiglutide 30 to 50 mg weekly or placebo, median follow-up 1.6 years. Primary composite (cardiovascular death, myocardial infarction, stroke): 338 of 4,731 (7 percent) against 428 of 4,732 (9 percent), hazard ratio 0.78 (95 percent CI 0.68 to 0.90), superiority P equals 0.0006. Pancreatitis 10 against 7, pancreatic cancer 6 against 5, medullary thyroid carcinoma 0 against 0. Funded by GlaxoSmithKline.
Lancet, 2018 · 9,463 people
- 23 people1 human study1 found nothing
found nothing23 women randomised double-blind to 250 mg of a 10 percent Coleus forskohlii extract twice daily (n equals 7) or placebo (n equals 12) for 12 weeks. No significant differences in fat mass, fat-free mass or body fat percentage. Non-significant trends toward mitigating gains in body mass (p equals 0.10) and scanned mass (p equals 0.08). Treated participants reported less hunger and fullness. No clinically significant changes in blood lipids, liver or muscle enzymes, thyroid hormones, insulin, heart rate or blood pressure. The authors concluded it does not appear to promote weight loss but may help mitigate weight gain.
Journal of the International Society of Sports Nutrition, 2005 · 23 people
- 3 people1 human study
Three children with congenital leptin deficiency treated with daily subcutaneous recombinant human leptin for up to 4 years: sustained reductions in appetite, fat mass, hyperinsulinaemia and hyperlipidaemia, rapid rise in thyroid hormones, appropriately timed puberty, and reversal of reduced CD4 T cell numbers and impaired T cell function. Non-US government funded.
Journal of Clinical Investigation, 2002 · 3 people
- 2 people1 human study1 found nothing
found nothingTwo adults received 10 mg intravenously on day 1 and 20 mg on day 2. No adverse effects were reported and cardiac, liver, kidney, thyroid and glucose laboratory values did not change meaningfully. Two subjects cannot characterise safety.
Alternative Therapies in Health and Medicine, 2025 · 2 people
- no headcount stated1 human study1 found nothing
found nothingThe first human study. Galanin infused for 60 minutes into healthy volunteers at 7.8 pmol/kg per minute (n=4) or 33.2 pmol/kg per minute (n=6). Plasma growth hormone rose from 2.8 to a mean peak of 48.5 mU/L at the high dose and from 2.5 to 23.5 mU/L at the low dose; prolactin rose from 176 to 274 mU/L. No change in cortisol, TSH, FSH or LH. No change in heart rate or blood pressure at these doses; the only symptoms were a transitory bitter taste and slight hypersalivation. Galanin reduced glucose clearance after an intravenous glucose bolus without significantly affecting plasma insulin.
The Lancet, 1986 · no headcount in the line
Why the trial record looks like this
A missing trial is usually a missing sponsor. Nobody runs a nine-figure programme on a molecule they cannot own, so the compounds with the thinnest human records are often the oldest and most freely available ones rather than the weakest. Taking Albiglutide as the example, because it states the problem most clearly:
Albiglutide is the counterexample this site needs against a comfortable assumption: that a drug which wins a large outcome trial on hard endpoints stays on the market. It reduced cardiovascular death, heart attack and stroke by 22 percent in 9,463 people, published in the Lancet in October 2018, and its European authorisation was withdrawn the same month, at the company's request, for what the EMA records as commercial reasons. Drugs@FDA lists it as discontinued. The only reasons on record are the sponsor's own phrases in the EMA notification and two registry entries: commercial reasons, business considerations, not quality, safety or efficacy. This profile does not go beyond them.
The evidence does, however, show what the drug was up against. In its own head to head trial it lowered HbA1c less than liraglutide and failed non-inferiority; its weight effect in the phase 3 programme was smaller than that of the lipidated analogues that followed; and by 2018 dulaglutide and semaglutide offered weekly dosing with larger glycaemic and weight effects. A drug can be genuinely protective and still be the weakest member of its class on the endpoints prescribers use to choose between members. Evidence and availability are different things, and albiglutide is the cleanest demonstration in the GLP-1 literature that they can come apart.
A compound appears here only when a citation on its own page states this outcome and reports a result for it; naming it is not enough. Human, animal and cell work are counted separately and never merged. Participant counts are read from the study lines and deliberately undercount. Nothing here is advice, and nothing here is a recommendation to take or to avoid anything.